These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 30767148)

  • 1. MiRNA-3653 Is a Potential Tissue Biomarker for Increased Metastatic Risk in Pancreatic Neuroendocrine Tumours.
    Gill P; Kim E; Chua TC; Clifton-Bligh RJ; Nahm CB; Mittal A; Gill AJ; Samra JS
    Endocr Pathol; 2019 Jun; 30(2):128-133. PubMed ID: 30767148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors.
    Marinoni I; Kurrer AS; Vassella E; Dettmer M; Rudolph T; Banz V; Hunger F; Pasquinelli S; Speel EJ; Perren A
    Gastroenterology; 2014 Feb; 146(2):453-60.e5. PubMed ID: 24148618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MicroRNAs associated with small bowel neuroendocrine tumours and their metastases.
    Miller HC; Frampton AE; Malczewska A; Ottaviani S; Stronach EA; Flora R; Kaemmerer D; Schwach G; Pfragner R; Faiz O; Kos-Kudła B; Hanna GB; Stebbing J; Castellano L; Frilling A
    Endocr Relat Cancer; 2016 Sep; 23(9):711-26. PubMed ID: 27353039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alternative Lengthening of Telomeres in Primary Pancreatic Neuroendocrine Tumors Is Associated with Aggressive Clinical Behavior and Poor Survival.
    Kim JY; Brosnan-Cashman JA; An S; Kim SJ; Song KB; Kim MS; Kim MJ; Hwang DW; Meeker AK; Yu E; Kim SC; Hruban RH; Heaphy CM; Hong SM
    Clin Cancer Res; 2017 Mar; 23(6):1598-1606. PubMed ID: 27663587
    [No Abstract]   [Full Text] [Related]  

  • 5. ATRX loss is an independent predictor of poor survival in pancreatic neuroendocrine tumors.
    Chou A; Itchins M; de Reuver PR; Arena J; Clarkson A; Sheen A; Sioson L; Cheung V; Perren A; Nahm C; Mittal A; Samra JS; Pajic M; Gill AJ
    Hum Pathol; 2018 Dec; 82():249-257. PubMed ID: 30081149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. miR-431 Promotes Metastasis of Pancreatic Neuroendocrine Tumors by Targeting DAB2 Interacting Protein, a Ras GTPase Activating Protein Tumor Suppressor.
    Zhang T; Choi S; Zhang T; Chen Z; Chi Y; Huang S; Xiang JZ; Du YN
    Am J Pathol; 2020 Mar; 190(3):689-701. PubMed ID: 31953039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. miRNA profiling of small intestinal neuroendocrine tumors defines novel molecular subtypes and identifies miR-375 as a biomarker of patient survival.
    Arvidsson Y; Rehammar A; Bergström A; Andersson E; Altiparmak G; Swärd C; Wängberg B; Kristiansson E; Nilsson O
    Mod Pathol; 2018 Aug; 31(8):1302-1317. PubMed ID: 29487354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An miRNA Signature Predicts Grading of Pancreatic Neuroendocrine Neoplasms.
    Saller J; White D; Hough B; Yoder S; Whiting J; Chen DT; Magliocco A; Coppola D
    Cancer Genomics Proteomics; 2023; 20(2):154-164. PubMed ID: 36870693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemically Detected Expression of ATRX, TSC2, and PTEN Predicts Clinical Outcomes in Patients With Grade 1 and 2 Pancreatic Neuroendocrine Tumors.
    Uemura J; Okano K; Oshima M; Suto H; Ando Y; Kumamoto K; Kadota K; Ichihara S; Kokudo Y; Maeba T; Nanno Y; Toyama H; Takada Y; Shimada M; Hanazaki K; Masaki T; Suzuki Y
    Ann Surg; 2021 Dec; 274(6):e949-e956. PubMed ID: 31599805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis.
    Zhang JX; Song W; Chen ZH; Wei JH; Liao YJ; Lei J; Hu M; Chen GZ; Liao B; Lu J; Zhao HW; Chen W; He YL; Wang HY; Xie D; Luo JH
    Lancet Oncol; 2013 Dec; 14(13):1295-306. PubMed ID: 24239208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EPB41L5 is Associated With the Metastatic Potential of Low-grade Pancreatic Neuroendocrine Tumors.
    Saller J; Seydafkan S; Shahid M; Gadara M; Cives M; Eschrich SA; Boulware D; Strosberg JR; Aejaz N; Coppola D
    Cancer Genomics Proteomics; 2019; 16(5):309-318. PubMed ID: 31467225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene Expression Signatures Identify Novel Therapeutics for Metastatic Pancreatic Neuroendocrine Tumors.
    Scott AT; Weitz M; Breheny PJ; Ear PH; Darbro B; Brown BJ; Braun TA; Li G; Umesalma S; Kaemmer CA; Maharjan CK; Quelle DE; Bellizzi AM; Chandrasekharan C; Dillon JS; O'Dorisio TM; Howe JR
    Clin Cancer Res; 2020 Apr; 26(8):2011-2021. PubMed ID: 31937620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive immunohistochemical analysis of histone deacetylases in pancreatic neuroendocrine tumors: HDAC5 as a predictor of poor clinical outcome.
    Klieser E; Urbas R; Stättner S; Primavesi F; Jäger T; Dinnewitzer A; Mayr C; Kiesslich T; Holzmann K; Di Fazio P; Neureiter D; Swierczynski S
    Hum Pathol; 2017 Jul; 65():41-52. PubMed ID: 28235630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overexpression of MicroRNA miR-7-5p Is a Potential Biomarker in Neuroendocrine Neoplasms of the Small Intestine.
    Heverhagen AE; Legrand N; Wagner V; Fendrich V; Bartsch DK; Slater EP
    Neuroendocrinology; 2018; 106(4):312-317. PubMed ID: 28848144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HDAC-Linked "Proliferative" miRNA Expression Pattern in Pancreatic Neuroendocrine Tumors.
    Klieser E; Urbas R; Swierczynski S; Stättner S; Primavesi F; Jäger T; Mayr C; Kiesslich T; Fazio PD; Helm K; Neureiter D
    Int J Mol Sci; 2018 Sep; 19(9):. PubMed ID: 30223590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of a metastasis-specific MicroRNA signature in human colorectal cancer.
    Hur K; Toiyama Y; Schetter AJ; Okugawa Y; Harris CC; Boland CR; Goel A
    J Natl Cancer Inst; 2015 Mar; 107(3):. PubMed ID: 25663689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alternative lengthening of telomeres and ATRX/DAXX loss can be reliably detected in FNAs of pancreatic neuroendocrine tumors.
    VandenBussche CJ; Allison DB; Graham MK; Charu V; Lennon AM; Wolfgang CL; Hruban RH; Heaphy CM
    Cancer Cytopathol; 2017 Jul; 125(7):544-551. PubMed ID: 28371511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. miR-629-3p may serve as a novel biomarker and potential therapeutic target for lung metastases of triple-negative breast cancer.
    Wang J; Song C; Tang H; Zhang C; Tang J; Li X; Chen B; Xie X
    Breast Cancer Res; 2017 Jun; 19(1):72. PubMed ID: 28629464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular alterations in sporadic pancreatic neuroendocrine microadenomas.
    Hadano A; Hirabayashi K; Yamada M; Kawanishi A; Takanashi Y; Kawaguchi Y; Nakagohri T; Nakamura N; Mine T
    Pancreatology; 2016; 16(3):411-5. PubMed ID: 26905832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Global microRNA profiling of pancreatic neuroendocrine neoplasias.
    Thorns C; Schurmann C; Gebauer N; Wallaschofski H; Kümpers C; Bernard V; Feller AC; Keck T; Habermann JK; Begum N; Lehnert H; Brabant G
    Anticancer Res; 2014 May; 34(5):2249-54. PubMed ID: 24778027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.